baricitinib sold brand name olumiant among others immunomodulatory medication used treatment rheumatoid arthritis alopecia areata acts inhibitor janus kinase jak blocking subtypes baricitinib approved medical use european united important side effect jak inhibitors serious bacterial mycobacterial fungal viral february baricitinib approved use european union secondline therapy moderate severe active rheumatoid arthritis adults either alone combination may us food drug administration fda approved baricitinib treatment adults moderately severely active rheumatoid arthritis inadequate response one tnf antagonist may fda approved baricitinib treatment hospitalized adults requiring supplemental oxygen noninvasive invasive mechanical ventilation extracorporeal membrane oxygenation baricitinib first immunomodulatory treatment receive fda united states baricitinib authorized emergency use authorization eua treatment hospitalized people aged less years age require supplemental oxygen noninvasive invasive mechanical ventilation extracorporeal membrane june fda authorized baricitinib treatment severe alopecia pregnancy use baricitinib studies upper respiratory tract infections high blood cholesterol levels hypercholesterolemia occurred patients less common side effects included infections herpes zoster herpes simplex urinary tract infections metabolized small extent substance low potential interactions studies inhibitors liver enzymes well inducer rifampicin relevant influence baricitinib concentrations bloodstream baricitinib blocks number transporter proteins vitro clinically relevant interactions via mechanism considered unlikely except perhaps cation transporter additive effect immunosuppressants baricitinib janus kinase jak inhibitor reversibly inhibits janus kinase half maximal inhibitory concentration nm janus kinase nm tyrosine kinase belongs enzyme family affected less nm janus kinase far less nm via signal transduction pathway involving stat proteins ultimately modulates gene expression immunological jak inhibitors include tofacitinib indicated treatment rheumatoid arthritis psoriatic arthritis ulcerative substance quickly absorbed gut absolute bioavailability reaches highest blood plasma levels hour different individuals time reach level ranges hours food intake relevant influence drugs pharmacokinetics circulating baricitinib bound blood plasma less substance metabolized four different oxidation products rest left unchanged elimination halflife hours average eliminated via urine via baricitinib discovered incyte licensed eli january eli lilly submitted new drug application us food drug administration fda approval baricitinib treat moderatelytoseverely active rheumatoid december committee medicinal products human use chmp european medicines agency ema recommended approval baricitinib therapy rheumatoid european union approval granted february despite widespread expectations fda would approve baricitinib rheumatoid april fda issued rejection citing concerns dosing may baricitinib approved united states treatment rheumatoid march us fda granted breakthrough therapy designation baricitinib treatment alopecia granted approval june efficacy safety baricitinib alopecia areata studied two randomized doubleblind placebocontrolled trials trial trial participants least scalp hair loss measured severity alopecia tool six participants trials received either placebo milligrams olumiant milligrams olumiant every primary measurement efficacy trials proportion patients achieved least scalp hair coverage week august clinical trials registered baricitinib phase trials update march phase iii clinical trial showed hair regrowth alopecia april lilly announced investigating use baricitinib treating people drugs antiinflammatory activity expected act inflammatory cascade associated april june first two studies baricitinib prescribed hospitalized patients published november published research showed baricitinib beneficial treating people according paper mechanistic actions janus inhibitor targeting viral entry replication cytokine storm associated beneficial outcomes including severely ill elderly clinical trial hospitalized people baricitinib combination remdesivir shown reduce time recovery within days initiating treatment compared participants received placebo data supporting us food drug administration fda emergency use authorization eua baricitinib combined remdesivir based randomized doubleblind placebocontrolled clinical trial conducted us national institute allergy infectious diseases clinical trial evaluated whether baricitinib impacted long took subjects also taking remdesivir recover trial followed participants days included participants moderate severe participants received baricitinib plus remdesivir participants received placebo plus recovery defined either discharged hospital hospitalized requiring supplemental oxygen longer requiring ongoing medical median time recovery seven days baricitinib plus remdesivir eight days placebo plus odds patients condition progressing death ventilated day lower baricitinib plus remdesivir group versus placebo plus remdesivir odds clinical improvement day higher baricitinib plus remdesivir group versus placebo plus remdesivir endpoints effects statistically eua issued eli lilly november world health organization updated guideline therapeutics include conditional recommendation use remdesivir triggered results solidarity november fda issued emergency use authorization eua combination baricitinib remdesivir treatment suspected laboratory confirmed hospitalized people aged two years age older requiring supplemental oxygen invasive mechanical ventilation extracorporeal membrane oxygenation september largest randomized placebocontrolled trial hospitalized patients date covbarrier trial randomized participants either baricitinib placebo nearly participants receiving systemic corticosteroids enrollment absolute risk reduction percent primary endpoint progression highflow oxygen noninvasive ventilation invasive mechanical ventilation death day statistically significant reduction allcause mortality participants receiving baricitinib compared placebo largest mortality reduction date maintained days translates one additional death prevented every patients treated baricitinib frequencies serious adverse events lower participants receiving baricitinib compared receiving placebocitation needed april committee medicinal products human use chmp european medicines agency ema evaluating use baricitinib include treatment hospitalized patients ten years age require supplemental july fda revised eua baricitinib authorizing alone treatment hospitalized people aged two years age older requiring supplemental oxygen noninvasive invasive mechanical ventilation extracorporeal membrane oxygenation revised eua baricitinib required administered january world health organization strongly recommended baricitinib patients severe critical thereafter february exploratory randomized placebocontrolled trial patients receiving invasive mechanical ventilation extracorporeal membrane oxygenation randomly baricitinib placebo statistically significant relative reduction allcause mortality participants receiving baricitinib compared receiving placebo days sustained may fda approved use baricitinib treatment adult patients hospitalized require supplemental oxygen noninvasive invasive mechanical ventilation extracorporeal membrane oxygenation recommended dose mg daily days hospital discharge whichever happens march recovery trial reported use baricitinib cut risk death fifth httpsenwikipediaorgwikibaricitinib